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ABSTRACT
Objectives: To assess the cost-effectiveness of alternative
strategies for the treatment of suspected inﬂuenza in other-
wise healthy adults and to identify future research priorities
using value of information analysis.
Methods: A decision model was used to estimate the costs
and effects, in terms of quality-adjusted life-years (QALYs) of
amantadine,zanamivir,and oseltamivir for the treatmentof in-
ﬂuenza in otherwise healthy adults using data predominantly
from meta-analysis of randomized controlled trials. Probabi-
listic sensitivity analysis using Monte Carlo simulation was
conducted. The expected value of perfect information for the
entire model and for individual parameters was calculated.
Results: Based on mean costs and effects, zanamivir is domi-
nated by oseltamivir. The incremental cost-effectiveness ratio
for amantadine (compared with no treatment) is £11,000 and
£44,000 for oseltamivir (compared with amantadine). The
probability that amantadine is cost-effective at a willingness
to pay of £30,000 perQALY is 0.74, falling to 0.49 at £20,000
per QALY. Global expected value of perfect information
(EVPI) is £2 m over 15 years if a willingness to pay threshold
of £30,000 per QALY is assumed rising to £9.6 m at £45,000
perQALY. EVPI for only one parameter exceeds £500,0000 at
£30,000 per QALY: the quality of life for untreated inﬂuenza.
Conclusions: At traditionally accepted values of willingness
to pay for health beneﬁts, it is unlikely that additional
research would be an efﬁcient use of scarce resources. The
only exception to this would be to examine the health-related
quality of life impact of inﬂuenza in an untreated patient
group. If a higher threshold value were acceptable, there are
a small group of parameters that may warrant further inves-
tigation. These would, however, require comparative, poten-
tially expensive, research studies.
Keywords: cost-utility analysis, inﬂuenza, probabilistic sensi-
tivity analysis, QALY, value of information.
Introduction
Inﬂuenza epidemics of varying intensity occur most
winters. The condition is usually self-limiting in people
who are relatively healthy, with typical symptoms such
as headache, fever, sore throat, cough, and aching
muscles and joints lasting several days. Nevertheless,
more severe, predominantly respiratory complications,
such as pneumonia and bronchitis, are the source of
substantial morbidity and increased mortality associ-
ated with inﬂuenza epidemics. In England and Wales,
an estimated 6200 to 29,600 additional deaths
occurred during each of the epidemics between 1975
and 1976 and 1989 and 1990 [1], about 10 times the
actual number of death certiﬁcations for inﬂuenza over
that time, suggesting that inﬂuenza is responsible for
many hidden deaths.
The principal component of public health strategies
aimed at controlling the burden of inﬂuenza is vaccina-
tion. In the UK, National Health Service vaccination is
offered to those considered at elevated risk of inﬂuenza
complications, either because of age or because of
concomitant disease, with uptake levels running at 69%
between 2002 and 2003 [2]. Two adamantanes, aman-
tadine (Lysovir; Alliance Pharmaceuticals Ltd., Chip-
penham, UK) and rimantadine (Flumadine; Alliance
Pharmaceuticals Ltd.), have been produced since the
mid-1960s for both treatment and prevention, although
the latter does not have a UK license and clinical uptake
of the former has been limited because of concerns over
adverse events, resistance, and its limited spectrum of
activity (adamantanes operate only against the replica-
tion of inﬂuenza A).
Neuraminidase inhibitors are a new class of antiviral
drugs that provide additional potential strategies for the
control of inﬂuenza. Zanamivir (Relenza; GlaxoSmith-
Kline, Brentford, UK) for the treatment of inﬂuenza is
administered bymeans of an inhaler andwas the subject
of one of the ﬁrst technology appraisals undertaken by
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theNational Institute for Clinical Excellence (NICE) [3]
in the UK. Guidance issued in 2000 recommendedNHS
use should be limited to “high-risk” groups. The launch
of oseltamivir (Tamiﬂu; F. Hoffman-La Roche, Ltd.,
Basel, Switzerland), taken orally and licensed for both
prophylaxis and treatment, prompted further review of
that guidance, and this article builds on evidence that
was submitted as part of that review [4].
This study examines the cost-effectiveness of
making amantadine, zanamivir, or oseltamivir avail-
able as treatments for individuals in the community
with suspected inﬂuenza, compared with no treatment.
A decision tree model is described and analyzed proba-
bilistically to estimate mean costs and QALYs for each
of the alternative strategies and to reﬂect uncertainty in
these outputs arising from the combined uncertainty in
model inputs. Probabilistic sensitivity analysis (PSA)
is increasingly recommended in guidelines for cost-
effectiveness analysis [5,6] as a means of quantifying
decision uncertainty to decision-makers.
Value of information analysis (VOI) has been seen
as a logical next step after PSA [7] but remains little
used in health technology assessment [8]. This set of
methods provide a formal framework in which the
value of collecting proposed new information, and
thereby reducing or eliminating uncertainty in model
parameters, is calculated with respect to the impact
that such reductions in uncertainty have on decision
uncertainty. Additional information has a value to the
extent that it reduces the probability that decision-
makers make a recommendation that is “incorrect,”
i.e., adopt a technology that is not in fact cost-effective.
Some of the methodological issues in VOI were ﬁrst
described by Claxton and Ades [9] using a simpliﬁed
cost-effectiveness model of zanamivir for the treatment
of inﬂuenza, and the technique is receiving increasing
attention within the health economics ﬁeld [10,11].
This article aims to contribute to that literature by
applying the technique to a substantive current decision
problem: the cost-effectiveness of antiviral treatment
for inﬂuenza in the UK. The analysis is restricted to
persons aged between 12 and 65 years considered to be
otherwise healthy.
Methods are presented in section 2. This section
describes the structure of the decisionmodel, parameter
values, and characterization of uncertainty. In addition,
the methods of analysis are presented. We outline here
how PSA is conducted and represented. This is followed
by a description of the methods for assessing VOI.
Results are in section 3 and discussion in section 4.
Methods
Model Structure
A probabilistic decision tree model was developed to
assess the cost-effectiveness of competing inﬂuenza
treatments in terms of additional cost to the UK
NHS per additional quality-adjusted life-year (QALY)
gained (Fig. 1).
The decision model is described in four separate
stages. The decision problem for the UK NHS is
described at stage one, namely,which of four alternative
inﬂuenza treatment strategies should be adopted:
amantadine (100 mg daily); zanamivir (10 mg twice
daily); oseltamivir (75 mg twice daily); or no drug
treatment. Each treatment course lasts 5 days. The
decision is relevant to a patient population that consists
of those with inﬂuenza-like illness (ILI) of whom only a
fraction will decide to consult with a family doctor
(stage 2). It is assumed that treatment with any antiviral
must be made within 48 hours of symptom onset, but
the model allows for individuals to receive (ineffective)
treatment after that time period because symptomonset
may be insidious and difﬁcult to recall accurately. Pre-
scription of antibiotics, instead of antivirals, may be
made at this initial general practitioner (GP) consulta-
tion (stage 3) where the practitioner suspects bacterial
infection rather than inﬂuenza. It is considered unlikely
that both antiviral and antibiotics would be prescribed
at this stage. Disease progression is described at stage 4.
The ﬁrst distinction made here is between those indi-
viduals who have genuine inﬂuenza rather than clini-
cally indistinguishable conditions such as bacterial
infections or other viruses (e.g., respiratory syncytial
virus). Near patient tests for inﬂuenza have recently
become available but are little used in the UK NHS
because of concerns over cost and speciﬁcity and are
therefore not considered in the model. No further costs
or beneﬁts beyond those already described are calcu-
lated in the model for patients who do not have inﬂu-
enza. Inﬂuenzamay be either strainAor strain B and the
distinction is important because amantadine is effective
only for the treatment of inﬂuenza A. True inﬂuenza
cases may experience complications that require a
revisit to the GP and that may result in pneumonia.
Appropriate antiviral treatment, i.e., treatment given to
inﬂuenza-positive patients within 48 hours of the onset
of illness, reduces the length of inﬂuenza illness, the
probability of complications requiring additional GP
visits, and the probability of developing pneumonia.
The model assumes that antiviral treatment does
not affect either hospitalizations or mortality. Several
previous studies have extrapolated from intermediate
data [12,13] to estimate these effects. Such events,
however, are extremely rare in an otherwise healthy
adult population and it was not considered credible
that antiviral drug treatment would impact on these
severe cases, an assumption that was also adopted by
the NICE technology appraisal committee in their con-
sideration of the evidence [14].
Parameter Values
Parameter values and associated probability distribu-
tions are recorded in Tables 1 and 2. These values were
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derived from the best available data. Primarily, meta-
analyses of randomized controlled trials (RCTs) were
used, but where no such sources were available, or
were considered either inappropriate or insufﬁcient,
they were supplemented or replaced with alternative
data, often from multiple sources [4].
Effectiveness. Overall effectiveness of each of the four
strategies was expressed in terms of Quality Adjusted
Life-years (QALYs) which were calculated as a combi-
nation of direct inﬂuenza related illness, pneumonia
and, in the case of amantadine, adverse drug events.
Four RCTs of oseltamivir versus placebo included
patients’ own reports of health-related quality of life
(HRQoL) (WV15670 [15],WV15671 [16],WV15730,
M76001) over a period of 21 days. Mean treatment
and placebo data were made available to us by the
manufacturer for the four trials combined. In the
absence of other HRQoL data for inﬂuenza, the trial
data were used both to estimate the number of
quality-adjusted life-days (QALDs) with no treatment
and the additional QALDs generated by oseltamivir
treatment. For these two arms of the model, direct
quality of life evidence was therefore used. For the
other two arms of the model (amantadine and zan-
amivir), no comparable data exist. Therefore, we com-
bined quality of life data from the four oseltamivir
trials with data on the length of inﬂuenza illness for
zanamivir and amantadine to estimate QALYs. This is
explained in more detail below.
The four trials consisted in excess of 1500 other-
wise healthy adults who were asked to complete a
visual analog scale that was marked between zero and
10. Zero on the scale was labeled “worst imaginable
health state” and 10 was labeled “normal health for
someone your age.” In a previous study using these
data, O’Brien et al. [13] simply transformed the
scores that patients gave onto a zero to one scale.
Given the labeling of the scales, however, this was not
considered appropriate. Two transformations were
therefore made to the raw data—ﬁrst, “normal health
for someone your age” was considered equivalent to
the mean valuation of own health from a large UK
survey [17,18]. Second, we transformed these data to
No GP 
consultation 
GP Consultation
Individual 
with influenza 
like illness
No NHS 
treatment 
available  
Amantadine
available  
Zanamivir 
available  
Oseltamivir 
available  Stage 1: NHS Policy 
Stage 2: Patient Behavior 
Within 48hrs of 
symptom onset 
After 48hrs of 
symptom onset
GP prescribes 
antiviral 
GP does not 
prescribe antiviral
Stage 3: GP Behavior 
Stage 4: Disease Progression 
Individual does not 
have influenza 
Individual has 
influenza A 
Recover with no 
further treatment 
Complication requiring 
revisit to GP 
Pneumonia
Individual has 
influenza B 
Figure 1 Model schematic.
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time-trade-off equivalent values using an algorithm
reported by the same study. For inﬂuenza-positive
patients who received placebo, the mean QALDs gen-
erated over the 21-day period were 15.13. The mean
additional QALDs generated by oseltamivir was
0.37.
For amantadine and zanamivir no comparable data
was available and length of illness was therefore used
to calculate QALDs. The mean length of inﬂuenza
illness was calculated for each of the four treatment
options and the QALDs generated under the zanamivir
and amantadine strategies calculated as a direct pro-
portion of length of illness:
QALDs QALDs
Difference in QA
zanamivir/amantadine no treatment= +
( LDs Difference in
length of illness
oseltamivir
zanamivir/ama
) (∗
ntadine
oseltamivir
Difference in
length of illness
/
) (1)
The length of illness for true inﬂuenza cases receiving
either no treatment or ineffective treatment (antiviral
after 48 hours of symptom onset, amantadine for inﬂu-
enza B) was calculated as 7.7 days (95% conﬁdence
interval [CI] 6.86–8.60) by random effects meta-
analysis of inﬂuenza-positive patients receiving placebo
in all neuraminidase inhibitor (NI) trials [4]. These eight
trials cover a number of years, and therefore inﬂuenza
strains, andwere thus considered an appropriate source
of data of the true long-term mean duration of symp-
toms. The reduction in length of illness for inﬂuenza-
positive patients receiving zanamivir was estimated to
be 1.68 days (95% CI 0.81–2.58), based on random
effects meta-analysis of ﬁve RCTs, and the equivalent
ﬁgure for oseltamivir, based on three RCTs, was
1.92 days (95% CI 0.94–2.92). Trial data for amanta-
dine come from studies over 30 years old and incorpo-
ration of these data into the decision model was
Table 2 Probability values
Parameter description Mean value
(95% Conﬁdence
interval) Probability distribution Source
Probabilities
ILI is inﬂuenza 0.46 0.425–0.494 Normal on Log of odds
(m = -0.16, SD 0.07)
[*] UK surveillance
Inﬂuenza is inﬂuenza A 0.684 0.484–0.884 Beta (a = 13.5, b = 6.25) [22] UK surveillance
Consulting the GP 0.282 (0.145–0.533)*
Annual excess GP
consultations due to
inﬂuenza
623,520 388,779–858,263 Lognormal (m = -13.3, SD
0.19)
[23,25] UK surveillance
Size of UK population 33,743,500 [24] UK census
Inﬂuenza attack rate 0.066 0.037–0.112 Normal on log of odds
(m = -2.66, SD 0.30)
[4] Random effects meta-analysis
of RCTs
Consulting GP within 48 hours
(conditional on consulting)
0.178 (0.150–0.212)
Consult on day 1 0.109 0.088–0.135 Normal on log of odds
(m = -2.1, SD 0.12)
[26] UK surveillance
Consult on day 2 0.093 0.037–0.117 Normal on log of odds
(m = -2.28, SD 0.13)
[26] UK surveillance
Rapid onset of symptoms 0.511 0.305–0.714 Normal on log of odds
(m = 0.05, SD 0.44)
[4] Random effects meta-analysis
of observational studies
Receive drug if after 48 hours 0.028 (0.015–0.045)
Dependent on same variables
as previous parameter
Receive drug if before 48 hours 0.952 0.775–1.000 Beta (a = 10, b = 0.5) Assumption
Antibiotic at ﬁrst visit—no
treatment strategy
0.42 0.417–0.423 Normal on Log of odds
(m = -0.32, SD 0.007)
[23] Observational study
Antibiotic at ﬁrst visit—antiviral
strategies
0.048 0.000–0.171 Beta (a = 0.5, b = 10) Assumption
Complication requiring return
GP visit—no treatment/
amantadine
0.371 0.362–0.380 Normal on Log of odds
(m = -0.53, SD 0.02)
[26,27] UK surveillance
Relative risk of complication—
zanamivir
0.741 0.575–0.954 Normal on log of relative risk
(m = -0.30, SD 0.13)
[4] Random effects meta-analysis
of RCTs
Relative risk of complication—
oseltamivir
0.423 0.160–0.930 Normal on log of relative risk
(m = -0.86, SD 0.38)
[4] Random effects meta-analysis
of RCTs
Pneumonia—no treatment/
amantadine
0.013 0.008–0.020 Normal on log of odds
(m = -4.35 SD 0.23)
[4] Random effects meta-analysis
of RCTs
Relative risk of pneumonia—
zanamivir
0.35 0.112–1.094 Normal on log of relative risk
(m = -1.05, SD 0.58)
[4] Random effects meta-analysis
of RCTs
Relative risk of pneumonia—
oseltamivir
0.15 0.060–0.720 Normal on log of relative risk
(m = -1.90, SD 0.78)
[4] Random effects meta-analysis
of RCTs
Antibiotic if complication
develops
0.814 0.806–0.822 Normal on Log of odds
(m = 1.48, SD 0.03)
[25] Observational study
Odds ratio adverse event—
amantadine
1.158 0.870–1.620 Normal on log of odds
(m = 0.17, SD 0.16)
[4] Random effects meta-analysis
of RCTs
*Supplied by London Health Protection Agency. ILI, inﬂuenza-like illness; GP, general practitioner; RCTs, randomized controlled trials.
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hampered by the use of duration of fever as an outcome
measure rather than inﬂuenza illness [19]. Therefore, a
meta-regression was constructed from all oseltamivir
RCTs (healthy adults, at-risk adults, and children),
which allowed the relationship between symptom and
fever duration to be estimated [4].We then used random
effects meta-analysis of amantadine trials that used the
currently recommended dose (100 mg/day) to estimate
the mean reduction in duration of fever. The estimated
mean reduction in length of illness for amantadine
treatment was 1.28 days (95% CI 0.81–1.73).
Little reliable data on inﬂuenza-related pneumonia
are available routinely and therefore the baseline rate of
pneumonia was based on random effects meta-analysis
of the placebo arms of NI RCTs. This rate of 0.013
(95% CI 0.008–0.02) was adjusted by the relative risk
of pneumonia from random effects meta-analysis in the
relevant trials of oseltamivir (0.15, 95% CI 0.06–0.72)
and zanamivir (0.35, 95% CI 0.11–1.09). No evidence
of any such effect was found in relation to amantadine
and it was considered credible to exclude this from the
amantadine strategy. The valuation of avoided pneu-
monia was drawn from Murray and Lopez [20].
Adverse events associated with neuraminidase
inhibitors have been shown to be extremely mild and
rare [4]. Conversely, amantadine is associated with a
more severe adverse event proﬁle, including events
relating to the central nervous system such as malaise,
depression, fatigue, vertigo, and “feeling drunk.”
These events were accounted for separately in the
model. Meta-analysis of two trials that examined
amantadine at the now recommended 100-mg dose
provided an estimated odds ratio of 1.18 (95% CI
0.87–1.62) [4]. This nonstatistically signiﬁcant result
and associated uncertainty is incorporated in the
model. Expert clinical opinion was sought to identify
the impact on quality of life of these symptoms by
estimating the likely EQ5D score and to estimate a
mean duration of symptoms of 5 days.
Data from the Royal College of General Practitio-
ners’ (RCGP) network of sentinel practices over
several years were used to estimate the probability that
ILI is inﬂuenza [21]. Clinicians submitted swabs from
patients presenting with ILI to the Central Public
Health Laboratory, Colindale, for laboratory analysis.
Data were provided by the authors relating to periods
when the RCGP consultation rates for inﬂuenza
exceed 50 per 100,000 population, the rate used to
deﬁne inﬂuenza epidemics that occur most seasons. In
those aged more than 15 years, the mean rate was 0.46
(95% CI 0.43–0.49) (D. Fleming and M. Zambon,
pers. comm.). It should be noted that this ﬁgure is
substantially lower than that observed in NI RCTs,
typically carried out by investigators who apply strict
clinical diagnostic criteria.
The probability that inﬂuenza is strain A was esti-
mated from 10 years of data published by the Public
Health Laboratory Service [Supplied by London
Health Protection Agency] (0.68, 95% CI 0.48–0.88).
The mean number of excess GP consultations for
ILI during inﬂuenza epidemic periods (compared with
when inﬂuenza is not circulating) over a 10-year
period was estimated by Fleming as approximately
600,000 in the healthy adult population [22]. By esti-
mating the size of the UK healthy adult population
[23] and the symptomatic inﬂuenza attack rate from
random effects meta-analysis of placebo recipients
participating in nine double-blind, placebo-controlled
inﬂuenza prevention trials [4], it was possible to esti-
mate the expected number of symptomatic inﬂuenza
cases per annum and thereby the proportion of those
who consult the GP: 600,000 divided by 2.2 million
(34 million ¥ 0.066).
The probability of attending within 48 hours of
symptom onset was estimated at approximately 20%,
11% on day 1 and 9% on day 2 [24]. Random effects
meta-analysis of published studies [4] was used to
estimate that 51% of inﬂuenza cases experience rapid
onset of illness. We assumed that half of those consult-
ing on day 2 could actually be later than 48 hours of
symptom onset because of insidious onset of inﬂuenza
and therefore unable to beneﬁt from any antiviral treat-
ment. The mean estimate of those presenting within
48 hours of symptom onset was therefore reduced by
2.2% (9% ¥ 0.5 ¥ [1–0.51]). Evidence exists that some
patients receive antibiotics at this initial GP consulta-
tion [25], but it was assumed that this would substan-
tially reduce where antivirals were prescribed. A beta
distribution (a = 0.5, b = 10) was ﬁtted to reﬂect uncer-
tainty around a mean probability of 0.05.
The baseline probability of an individual develop-
ing an inﬂuenza complication was estimated as the
proportion requiring a repeat GP consultation based
on RCGP data [26,27] (0.37, 95% CI 0.36–0.38). The
relative risk of developing complications requiring an
antibiotic based on NI RCTs was 0.74 (95% CI 0.58–
0.95) and 0.42 (95% CI 0.16–0.93) for zanamivir and
oseltamivir, respectively [4]. This measure was consid-
ered the most realistic proxy measure for repeat GP
consultations in NHS practice available from RCTs
because repeat consultations themselves were often
part of the study protocol.
No evidence of reductions in complications of any
type was identiﬁed for amantadine. Amantadine does
have a relatively poor evidence base compared with the
newer NIs. Nevertheless, it was also considered the
most credible scenario that amantadine does not
impact on repeat GP consultations, antibiotic use, or
pneumonia. It can be observed that amantadine is little
used in practice at least in part because of concerns
over its lack of effectiveness.
Costs. Cost data, also shown in Table 1 and expressed
in 2001 prices, were drawn predominantly from UK
Neuraminidase Inhibitors for Inﬂuenza 165
published sources [28,29]. All drug costs were inﬂated
to include pharmacy prescribing fees and container
allowances (Prescriptions Pricing Authority, pers.
comm.).
Characterization of Uncertainty
In all meta-analyses, a random effects model was used
and it is the uncertainty around these pooled means
that is reﬂected in the probability distributions. This is
to reﬂect the fact that the model is concerned with
mean costs and effects over a long period. Some
parameters, such as the probability that ILI is inﬂu-
enza, will vary from year to year and using advanced
surveillance or near patient tests may increase the
ability to predict on an annual basis. In such a situa-
tion, predictive distributions may be more appropriate
[30], but this was not the aim of the modeling pre-
sented here.
Parameters were considered independent. Normal
distributions were assigned to log relative risks and log
odds ratios. A normal distribution was also considered
appropriate for the reduction of length of illness and
the difference in QALYs for oseltamivir. A log-normal
distribution was ﬁtted to the length of illness and
excess GP consultations because this imposes a lower
bound of zero with no upper bound and positive skew-
ness. Beta distributions were ﬁtted where a bound of
zero to one was considered appropriate, i.e., for the
QALY more than 21 days without treatment and for
some probabilities.
Analysis
The model was evaluated probabilistically. Monte
Carlo simulation was used to generate a large number
of random samples from the parameter probability
distributions. Cost-effectiveness acceptability curves
(CEACs) were generated to reﬂect the uncertainty
inherent in the model parameters. The costs, beneﬁts,
and net beneﬁts of each strategy were calculated for
each of the Monte Carlo simulations by the following
equation:
Expected net beneﬁt Ti Q Ti C Ti= ( ) − ( )λ.
Where l represents the maximum acceptable incre-
mental cost-effectiveness ratio (ICER) or “willingness
to pay” threshold; Q(Ti) is the expected health beneﬁt
of treatment strategy Ti, and C(Ti) is the expected cost
of treatment strategy Ti [31]. A strategy is considered
optimal if it generates the highest mean net beneﬁt.
The CEAC plots the proportion of simulations for
each strategy that generate the maximum net beneﬁt
across a l range of £0 to £80,000, thereby providing a
clear link between the uncertainty in model parameters
and the outputs of the model. That is, for any l, the
CEAC displays the probability that a given strategy is
cost-effective (incrementally). The CEAC frontier plots
the extent of uncertainty associated with the optimal
strategy (i.e., the strategy generating the greatest mean
net beneﬁt) across a similar range of l-values [32].
VOI. Decision-makers must make a choice as to
which of the four treatment strategies should be
adopted at the current time despite uncertainty in cost-
effectiveness estimates arising from uncertainty in
input parameters. The true cost-effectiveness of any
strategy may be different from the values estimated in
the model and therefore decision-makers may make
choices that are actually “incorrect.” A second deci-
sion that may be taken with respect to any technology
is to attempt to reduce the level of uncertainty by
commissioning additional research. VOI provides a
rational framework within which that research can be
prioritized on the basis of the expected value of reduc-
tions in particular elements of uncertainty in the deci-
sion analytic model.
One branch of VOI is expected value of perfect
information (EVPI) analysis. EVPI is a Bayesian
approach that works by taking current knowledge (a
prior probability distribution), adding in proposed
information to be collected (data), and producing a
posterior distribution (synthesized probability distri-
bution) based on all available information. The collec-
tion of some types of additional data may lead to a
different adoption decision, which is the recommenda-
tion of a different strategy to that which would be
recommended based on current information. For other
additional data the adoption decision may not change.
EVPI is obtained by simulating additional information,
considering whether this data would result in a revised
adoption decision, and quantifying the net beneﬁt of
our original baseline decision as compared with the
extra net beneﬁt provided by the revised decision given
new data.
Two types of EVPI analysis are reported here.
Global EVPI provides an estimate of the value of elimi-
nating all uncertainty in the model and therefore rep-
resents a ceiling value on the cost of future research.
Partial EVPI estimates the value of eliminating all
uncertainty associated with individual parameters or
groups of parameters, providing an upper boundary
for the cost of additional research into speciﬁc issues.
Given the wide range of data sources used in this
model, partial EVPI is particularly useful.
The two-stage integration required for EVPI on
subsets of parameters [7] was implemented as a two-
stage, nested, Monte Carlo algorithm (see, e.g., Tap-
penden et al. [31]). A “short cut” approach, which
does not require an outer loop of simulation, may be
appropriate for many decision tree models with inde-
pendent parameters. Although parameters are inde-
pendent throughout in this model, the relationship
with net beneﬁt is not linear for all parameters and for
this reason the two-stage approach was implemented
[7,33].
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Uncertainty is characterized to reﬂect two issues:
true data uncertainty and also variability. For example,
the proportion of ILI that is inﬂuenza is dependent on
the strain of inﬂuenza, which varies from year to year.
No amount of data could correctly predict the strain
that may emerge in the next year. There is therefore a
degree of variability as well as uncertainty. This analy-
sis does not distinguish variability from uncertainty
and therefore the EVPI estimates presented relate
to both. Nevertheless, a policy decision taken by a
decision-maker such as NICE is expected to hold over
a period of many years and that decision should there-
fore be based on the long-run mean value, in the
absence of predictors of intensity of epidemic from
year to year.
EVPI is dependent on the size of the population and
the timescale over which the technology is relevant.
The number of persons developing ILI during the
inﬂuenza epidemic season can be estimated as the
size of the UK healthy adult population [23]
(34 million) ¥ inﬂuenza attack rate [4] (0.066) ¥ cases
of ILI per case of inﬂuenza (D. Fleming and M.
Zambon, pers. comm.) (1/0.46). This provides a
central estimate of 4.1 million cases per annum.
Results are presented for assumed 5-, 10-, and 15-year
time horizons, with values generated in future years
discounted at 6% per annum.
Results
Cost-Effectiveness
Table 3 presents the mean costs, beneﬁts and cost-
effectiveness ratios, and associated 95% CIs per
person with ILI. Differences in beneﬁts (QALDs)
between strategies are relatively small because for
each strategy only a small proportion of patients actu-
ally receive effective antiviral treatment (either they
do not visit the GP at all or they do so after 48 hours,
they do not have inﬂuenza, or they do not receive
antiviral treatment). The cost-effectiveness ratios indi-
cate that for each additional QALY generated by the
amantadine strategy compared with no treatment, an
additional cost of £11,000 is incurred. Both of the
neuraminidase inhibitors are more effective and more
costly than amantadine. Oseltamivir dominates zan-
amivir and generates additional QALYs at £32,000
compared with no treatment and £44,000 compared
with the next most effective treatment that is not
dominated (amantadine).
The CEACs are plotted for the l range £0 to
£80,000 in Figure 2. At each value of l the four indi-
vidual CEACs (one for each treatment strategy) indi-
cate the proportion of the 10,000 Monte Carlo
simulations in which that strategy was optimal, i.e.,
generated the maximum net beneﬁt. Where l is equal
to £30,000, for example, it can be seen that the prob-
ability that no treatment, amantadine, zanamivir, or
oseltamivir are the optimal strategy is approximately
0.20, 0.74, 0.02, and 0.05, respectively. Note that
because these are mutually exclusive options, these
proportions sum to unity: only one strategy can be
optimal in a single simulation. The CEAC also high-
lights that, where l is £40,000, the probabilities that
amantadine or oseltamivir are the optimal strategies
are approximately equal (0.49 and 0.42, respectively).
The CEAC frontier in Figure 2 illustrates that where
l is less than £11,000, the optimal strategy is no treat-
ment. Between £11,000 and £44,000 the optimal strat-
egy is amantadine, and where willingness to pay per
QALY exceeds £44,000, oseltamivir is the optimal
strategy.
EVPI
Global EVPI was calculated as the difference between
expected net beneﬁt given full information (all param-
eters resolve at their mean values) and the expected net
beneﬁt given current information [31]. Figure 3 plots
the global EVPI per person as a function of l between
£0 and £80,000. Results are presented for time hori-
zons of 1, 5, 10, and 15 years. There are local peaks
around the mean ICERs for amantadine (£11,000) and
oseltamivir (£44,000) and the functions rise again as
l rises. Although the second of these peaks indicates
the global EVPI for the population lies between
£9.6 million (15-year lifetime) and £0.9 million
(1-year lifetime), these values are much lower at con-
ventionally accepted values of l. For example, where l
is equal to £30,000, the global EVPI is approximately
£2 million (15-year lifetimes).
EVPI for individual parameters identiﬁes the reason
for the shape of the global EVPI functions. For each of
the uncertain parameters, EVPI was calculated as the
Table 3 Base case costs and QALYs
Strategy
Mean
cost (£) (95% CI)
Mean
QALD (95% CI)
Cost per QALY-
compared with
no treatment (£)
Cost per
QALY (£)
(ICER)
No treatment 10.99 (7.55–16.66) 6.925 (6.358–7.494) —
Amantadine 11.09 (7.60–16.85) 6.929 (6.359–7.498) 10,824 10,824
Zanamivir 12.27 (8.20–18.99) 6.935 (6.366–7.505) 49,405 Dominated
Oseltamivir 11.88 (8.00–18.27) 6.936 (6.367–7.503) 32,406 44,420
ICER, incremental cost-effectiveness ratio; QALD, quality-adjusted life-day; QALY, quality-adjusted life-year.
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difference in expected net beneﬁt given full informa-
tion and expected net beneﬁt given current informa-
tion about the parameter in question. Figure 4 and
Table 4 show the results for those parameters where
EVPI was greater than £100,000 for any l between £0
and £60,000, assuming a 10-year time horizon. These
parameters generate values with local maxima at the
mean ICER values of each of the three drug interven-
tions, as with the global EVPI.
The global maximum occurs at a cost effectiveness
threshold of approximately £44,000 for most param-
eters shown in Figure 4 and Table 4, the ICER associ-
ated with oseltamivir. This is the case even for those
parameters that relate to the effectiveness of amanta-
dine, e.g., the relative risk of an adverse event as a
result of amantadine treatment. This is because the
cost-effectiveness of oseltamivir is dependent on the
effectiveness of the next best alternative, which in most
simulations is amantadine. The EVPI for three param-
eters continues to rise beyond l of £60,000. These are
parameters that inﬂuence the relative cost-effectiveness
of oseltamivir compared with zanamivir, namely, the
QALYs for no treatment and reduction in illness days
associated with oseltamivir and zanamivir. It should be
noted that there is substantial variation in the EVPI for
each parameter dependent on l. In many cases, the
EVPI is low at a threshold value of £30,000 per QALY.
The EVPI for four parameters exceeds £1 million
where l is equal to £45,000 and a lifetime of 10 years
is assumed. These are the relative risk of adverse events
for amantadine, the QALYs generated by no treat-
ment, and the reductions in length of illness for
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oseltamivir and amantadine. The latter two values
exceed £2 million.
Discussion
This article reports a study that compares existing and
newer strategies for the treatment of inﬂuenza in oth-
erwise healthy adults. Data are drawn primarily from
meta-analysis of RCTs and, by utilizing best available
evidence throughout, are synthesized in a decision ana-
lytic cost-effectiveness model.
The model is evaluated probabilistically by specify-
ing uncertain parameters as probability distributions
and using Monte Carlo simulation to sample from
those probability distributions a large number of
times. Mean cost-effectiveness ratios indicate that
amantadine is the optimal strategy, assuming
l = £30,000, and that oseltamivir is the optimal strat-
egy where l exceeds £44,000. CEACs highlight the
degree of uncertainty associated with these estimates.
If decision-makers are willing to pay £40,000 per
QALY, then the probability that amantadine is optimal
is very similar to the probability that oseltamivir is
optimal.
EVPI extends this analysis of uncertainty by identi-
fying those areas where additional information may be
particularly useful. Global EVPI estimates the value of
eliminating all uncertainty and thereby serves as an
upper bound on the cost of future research. Dependent
on the value of l and the time horizon for the tech-
nologies, this value may be as high as £10 million.
EVPI for individual parameters highlights that the
uncertainty in many parameter estimates does not play
a signiﬁcant part in decision uncertainty and therefore
further studies would not be valuable. In particular,
where l is £30,000 it is unlikely that any further
research would be an efﬁcient use of scarce resources.
The only exception at this threshold value is the
parameter for QALYs on no treatment. The EVPI at
this level is £741,000, and because additional informa-
tion on this parameter could be gathered through
observational rather than comparative studies, further
research is unlikely to be particularly costly. Some
cautions, however, are necessary in relation to poten-
tial additional research. The ﬁnding may be an artifact
of the way the data were analyzed. Given that the
current estimate is based on trials of approximately
1500 patients, signiﬁcant reductions in uncertainty are
0
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Figure 4 Expected value of perfect informa-
tion (EVPI) for parameters—10-year time
horizon.
Table 4 Expected value of perfect information for parameters—10-year time horizon
Probabilities
Flu is ﬂu A
Relative risks
Quality of life
No treatment
Reduction in length of illness
Pneumonia—
oseltamivir
Complication—
oseltamivir
Adverse event—
amantadine Oseltamivir Amantadine Zanamivir
Willingness to pay threshold
0 0 0 0 0 0 0 0 0
10,000 89,759 0 0 168,571 152,005 408,536 367,557 0
20,000 55,492 0 0 96,742 420,716 148,100 84,538 0
30,000 64,033 0 0 74,984 741,080 227,606 0 0
40,000 449,062 0 0 763,628 1,017,929 1,437,403 913,960 8,490
45,000 711,455 371,140 394,141 1,115,298 1,105,396 2,489,000 2,057,917 67,080
50,000 83,035 40,153 30,654 313,024 1,194,083 2,102,078 1,073,156 129,245
60,000 0 0 13,432 23,269 1,373,137 2,263,583 291,225 310,511
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only likely with extremely large samples. A logical
approach would be to examine the existing data in a
more disaggregated way than was possible here, e.g.,
at the trial or at the patient level, before recommending
more data collection. The use of expected value of
sample information analysis, which estimates the
expected value of reducing uncertainty in a similar
fashion to EVPI, may be of particular importance if
additional data collection is to be considered.
It is only at higher threshold values that the EVPI
becomes substantial for a number of parameters that
could only be examined further through comparative
studies. Of the three parameters that generate EVPI in
excess of £1 million at l = £45,000, one relates to
oseltamivir (reduction in length of illness) and two
relate to amantadine (reduction in length of illness and
relative risk of an adverse event). Further clinical trials
of oseltamivir or amantadine may then be warranted,
particularly because such studies would inform a
number of other parameters such as the relative risk of
complications and pneumonia, which themselves gen-
erate signiﬁcant, albeit lower, EVPI. This is, however,
only if decision-makers are willing to pay a higher
amount per unit of health beneﬁt than is considered
customary in the UK.
Other parameters have lower EVPIs. Monitoring of
the proportion of ILI that is true inﬂuenza and the rate
of inﬂuenza A to overall inﬂuenza is currently under-
taken routinely by the Health Protection Agency for
surveillance purposes and therefore the low EVPI is
less relevant for these parameters. EVPI for these
parameters in particular indicates both the value of
parameter uncertainty and inherent variability from
season to season. Near patient tests, currently consid-
ered insufﬁciently sensitive and excessively costly for
routine use in the NHS, could be used to improve the
ability of the individual GP to distinguish inﬂuenza
correctly. Improvements in near patient testing might
enable better targeting of antivirals to those able to
beneﬁt and thereby increase the beneﬁts of treatment.
An alternative approach would be to lower the cost of
administering treatments, e.g., by allowing nurse or
telephone prescribing, or by allowing sales of NIs
“over the counter.”
An additional complicating factor relating to many
parameters in the model is that reducing uncertainty
has a value for other decisions in addition to the treat-
ment of inﬂuenza in the otherwise healthy adult popu-
lation. These drugs have prophylactic uses, seasonal,
postexposure and pandemic, and are also available for
other patient groups (at-risk adults and, in the case of
oseltamivir, children). One of the future challenges for
VOI analysis is the development of methods that rec-
ognize the interaction between different decisions.
EVPI is dependent on estimates of the size of the
population, the time horizon over which technologies
are relevant and the discount rate. These parameters
are themselves uncertain, although only simple sensi-
tivities relating to the time horizon have been pre-
sented here for the sake of clarity.
Furthermore, EVPI is dependent on the speciﬁca-
tion of the decision model and the characterization of
uncertainty, each of which are potentially controver-
sial. Alternative speciﬁcations have the potential to
impact either solely on the degree of uncertainty in the
model and therefore the estimates of EVPI, or on the
central estimates of cost-effectiveness. Two examples
illustrate.
First, if it is assumed that NIs reduce mortality and
hospitalizations in the same proportion as observed
reductions in pneumonia cases, the cost per QALY for
oseltamivir would reduce to approximately £5000
compared with amantadine and thereby signiﬁcantly
reduce uncertainty (assuming that l exceeds £20,000
per QALY). Second, QALYs could be estimated by
using only the observed baseline QALDs, ignoring
data on the additional QALDs on oseltamivir treat-
ment and adjusting according to length of illness for
each of the three drug strategies, including oseltamivir.
This strategy has no impact on the mean cost per
QALY but would change the method by which the
length of illness and QALY parameters are used in the
model and thereby the impact of uncertainty associ-
ated with each parameter. EVPI estimates are altered
by such structural changes in the model.
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